Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 15Active not recruiting 14Terminated 6Completed 6Withdrawn 2Not yet recruiting 2Unknown 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3Head & Neck 3Gastrointestinal 2Breast 2Genitourinary 1

Conditions

Colorectal Neoplasms 1Barrett Esophagus 1

Interventions

Fluorouracil 51Oxaliplatin 49Gemcitabine 47Leucovorin 41Capecitabine 35Bevacizumab 29Irinotecan 25Cisplatin 22Radiotherapy 18Radiosurgery 18pembrolizumab 16Nivolumab 16Cetuximab 15Taxes 14Sorafenib 14Paclitaxel 13Biopsy 13Surgical Procedures, Operative 12Drug Therapy 11atezolizumab 10Radiation 10Albumin-Bound Paclitaxel 10lenvatinib 9durvalumab 9Magnetic Resonance Spectroscopy 9Folfox protocol 9Cyclophosphamide 9130-nm albumin-bound paclitaxel 9spartalizumab 8Chemotherapy, Adjuvant 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × X-Rays × Gastrointestinal × Clear all
NCT06730100 2025-10-06

CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Gastrointestinal

Colorectal Neoplasms

NCT01209013 2012-05-08

Oedisse

Pinnacle Biologics Inc.

Phase 3 Withdrawn
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡